Product Datasheet

NX-2127

Catalog No. **BP-02011** · CAS **2416131-46-7** · Form **free base** · Physical state **other** · Color **Light yellow to yellow** · Version **1.0** · Revision **2026-09-11**

FOR RESEARCH USE ONLY. NOT FOR HUMAN OR VETERINARY USE.

Target	Research area
PROTACs; Btk	**Cancer**

Molecular formula	$C_{39}H_{45}N_9O_5$
Molecular weight	**719.8300**

STRUCTURE



DESCRIPTION

NX-2127 is an orally and potent BTK inhibitor, inducing degradation of the mutated BTKC481S in cells. NX-2127 inhibits proliferation of BTKC481S mutant TMD8 cells. NX-2127 catalyzes the degradation of Ikaros (IKZF1) and Aiolos (IKZF3) with of 25 nM and 54 nM, respectively. NX-2127 stimulates T cell activation and increases IL-2 production in primary human T Cells.

BIOLOGICAL ACTIVITY

Zelebrudomide (NX-2127) is an orally active, potent BTK inhibitor that induces degradation of mutant BTKC481S in cells, as well as inhibits the proliferation of BTKC481S mutant TMD8 cells. In addition, NX-2127 stimulates T cell activation and increases IL-2 production in primary human T cells.

SOLUBILITY

Soluble in DMSO

In vitro	DMSO : 100 mg/mL

REFERENCES

[1]. Robbins DW, et al. Discovery and Preclinical Pharmacology of NX-2127, an Orally Bioavailable Degrader of Bruton's Tyrosine Kinase with Immunomodulatory Activity for the Treatment of Patients with B Cell Malignancies. Journal of medicinal chemistry. 2024 Feb 22;67(4):2321-2336.